Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2020 06:00 ET | Source: Novavax, Inc.

Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May

NVX-CoV2373 identified as SARS-CoV-2 candidate for Phase 1 clinical trialIn preclinical studies, NVX-CoV2373 demonstrated high immunogenicity and stimulated high levels of neutralizing...
March 24, 2020 06:00 ET | Source: Novavax, Inc.

Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial

Trial also achieves statistical significance in key secondary endpointsNovavax to submit a U.S. BLA under FDA’s accelerated approval pathwayCompany to host investor conference call today at 8:30 a.m....
March 11, 2020 16:17 ET | Source: Novavax, Inc.

Novavax Reports Fourth Quarter and Full Year 2019 Financial Results

NanoFlu top-line data from Phase 3 clinical trial expected by the end of this monthNovavax awarded CEPI funding to support COVID-19 vaccine programCOVID-19 Phase 1 clinical trial expected to initiate...
March 11, 2020 10:45 ET | Source: Novavax, Inc.

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford UniversityPhase 2b clinical efficacy study of experimental malaria...
March 10, 2020 05:30 ET | Source: Novavax, Inc.

Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trialsPhase 1...
March 05, 2020 16:05 ET | Source: Novavax, Inc.

Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020

GAITHERSBURG, Md., March 05, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
February 26, 2020 09:27 ET | Source: Novavax, Inc.

Novavax Advances Development of Novel COVID-19 Vaccine

Vaccine candidate derived from coronavirus spike (S) proteinMatrix-M™ adjuvant expected to boost immune responsesPhase 1 clinical trial planned for late spring GAITHERSBURG, Md., Feb. 26, 2020 ...
February 25, 2020 16:05 ET | Source: Novavax, Inc.

Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity

GAITHERSBURG, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
January 15, 2020 08:30 ET | Source: Novavax, Inc.

Novavax Granted Fast Track Designation for NanoFlu in Older Adults

GAITHERSBURG, Md., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
January 09, 2020 16:05 ET | Source: Novavax, Inc.

Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference

GAITHERSBURG, Md., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right